drugset / Trial / NCT05546060

Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

NCT05546060

Phase 1 Unknown 20 enrolled Beijing Friendship Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study aimed to investigate the efficacy and safety of venetoclax combined with dexamethasone and etoposide as a salvage therapy for hemophagocytic lymphohistiocytosis.

Timeline

Start
2022-07-01
Primary completion
2025-07-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 1.25 mg/m2
Subject Etoposide Small molecule 75 mg/m2
Subject Venetoclax Small molecule 400 mg